371 results about "Test agent" patented technology

The present invention is directed to a method for determining the effect of each of a plurality of test agents on cells from a subject, and a method to profile patient cell responses to test agents.

Systems and methods for providing a boundary scan test of a wired or wireless network having a plurality of network nodes are presented. The system includes a test station communicatively coupled with the network. The test station creates a MAC layer scan test route sequence that includes each link in the network and is independent of the routing mechanism and protocol used for the network. The test station also creates a test agent that is configured to traverse each link in the scan test route sequence. The test agent is then deployed on the network and information about a link is reported back to the test station after the test agent examines the link. The scan test route sequence can be created by sending out a series of broadcast messages from one or more nodes in the network, sequentially applying a network tour to cover the entire network, or performing a depth first search on the entire network.

Dynamic filtering methods, systems and computer program products are provided for network performance test results which may apply network troubleshooting expertise and knowledge of network topology to select and display test results in a manner which may facilitate analysis of those results by IT staffs. In a further aspect of the present invention, a severity index is provided which may be generated based on exception events from a plurality of network performance measurements, for example, response time, throughput and availability, which measurements are generated from test results obtained from agents located on various devices on a computer network. The test results may be obtained from either passive application monitor agents or active network test agents. In another aspect of the present invention, the exception events may be detected based on automatically generated threshold criteria which may be provided user selectable sensitivity and may be based on a specified percentage criteria relative to baseline performance results. In a further aspect of the present invention, the test results may be stored using data buckets with the number of data buckets and / or the range of each of the data buckets being selected to provide a desired overall range and granularity for each of the plurality of network performance measurement types. The range (width) of some of the data buckets may be narrower than others to provide greater resolution in a region of interest.

A method and system is disclosed which is capable of delivering at a high dose rate, respirable solid aerosols derived from aqueous- or nonaqueous-based solutions containing the desired therapeutic agent(s). The method and system comprises the integration of an aerosol generator, an aerosol evaporator, an aerosol concentrator, and an aerosol flow regulator. The aerosol generator generates 10-30 μm droplets, with a narrow size distribution. The aerosol jet is arrested by a coaxial counter-flow heated air jet, and evaporated rapidly by annular swirling heated air. Most of the air, together with the unwanted solvent vapor, is removed from the aerosol stream during the process of aerosol concentration. The output aerosol carries the dry particles to be inhaled by the patient. The respiratory-governed control of aerosol fluid generation system delivers fluid containing the test agent of interest (drug or toxin) to the aerosol generator throughout inhalation.

Systems and methods for providing a boundary scan test of a wired or wireless network having a plurality of network nodes are presented. The system includes a test station communicatively coupled with the network. The test station creates a MAC layer scan test route sequence that includes each link in the network and is independent of the routing mechanism and protocol used for the network. The test station also creates a test agent that is configured to traverse each link in the scan test route sequence. The test agent is then deployed on the network and information about a link is reported back to the test station after the test agent examines the link. The scan test route sequence can be created by sending out a series of broadcast messages from one or more nodes in the network, sequentially applying a network tour to cover the entire network, or performing a depth first search on the entire network.

Various systems and methods for testing one or more servers using a distributed test system may involve a master agent synchronously transitioning multiple test agents through several state changes. In some embodiments, a method may involve configuring multiple test agents to execute a test by initiating a state change to a first state at each of the test agents. Each of the test agents is prepared to execute the test when in the first state. Each of the test agents simulates multiple clients of a server under test when executing the test. In response to each of the test agents confirming the state change to the first state, a state change to a second state may be initiated at each of the plurality of test agents. Each of the test agents executes the test when in the second state.

A storage area network simulator, operable to simulate an exchange of calls emanating from a SAN management application to a plurality of manageable entities, allows analyzing SAN management application response to a particular configuration. A capture tool discovers manageable entities interconnected in a particular SAN experiencing undesirable operation. The capture tool provides exemplary calls to an agent, and gathers responses. The exemplary calls enumerate expected responses from the various manageable entities responsive to the agent. The gathered responses take the form of an XML markup script. A simulation plug-in is operative as an interface module (e.g. plug-in) for a test agent in a test environment, such as the management application test facility. The test agent employs the simulation plug-in as the API plug-in for calls emanating from the test agent. The plug-in receives the normalized responses, and selectively transmits the corresponding response from the gathered normalized responses in response to agent calls received via the API.

A method for discovering neurogenic drugs is revealed. The method allows for systematic screening of test agents such as libraries of compounds. The method consists of exposing test agents to cultures of differentiating neural progenitor cells and measuring their effects on increasing the overall cell number and / or the number of neurons.

A screening method can be used to determine whether a subject is a suitable candidate for interventional therapy. The method can be used to determine the likelihood the subject will receive a therapeutic effect from denervation therapy. The determination is based, at least in part, on lung information obtained by performing lung function tests with and without treating the subject's lungs with a test agent. Based on the response to a test agent, the subject's response to a therapy is predicted.

A method is provided for diagnosing and monitoring kidney disease or a predisposition to kidney disease, in a subject comprising detecting pVHL, VEGF-A, CXCR4, integrin β-1, PDGF-A, HIF1α and / or TGFβ in a sample from the subject. Screening methods for test agents for inhibiting kidney disease, and therapeutic applications are also described.

A liquid transfer device is provided for biochemical assay, including a pipette forming an interior space extending in an axial direction and having first and second ends. The first end forms an opening and the second end forms an enclosed variable volume, whereby variation of the volume causes a change of pressure to selectively induce a suction force and a releasing force in the pipette. An analysis container includes a plurality of receptacles retained by a slab. A film covers the slab to seal the container. A movement control device includes a manipulator that releasably holds the pipette and a tray that forms a cavity for receiving and retaining the container. The pipette and the tray are movable with respect to each other in order to fill / draw test agent into / out of the receptacles.

The invention discloses an integrated test system and a relevant method for distributed software systems. The system comprises a test server, at least one test client end and at least one test agent; the test server is respectively connected with the test client end and the test agent, in order to fulfill test on external systems under test according to test information; meanwhile, feed the test results back to the test client end; the test client end is used to receive and transmit test information, control the test server to perform tests, and receive test results; the test agent is also linked to a system under test through an interface for the system under test, in order to monitor message that are received and transmitted through the interface; meanwhile, the test agent is respectively interactive and adaptive with the test server and the system under test, and receives and transmits test message as well as relevant response message. Therefore, the invention adapts to test the second generation of distributed software systems that are fulfilled with distributed computation technology, increases and improves test tool expansibility and integrated test efficiency, and makes for execution of all types of integrated tests and guarantees quality of software products.

The present invention provides a method and system for evaluating wireless applications utilizing a test console, an application model builder, a test repository manager, a simulator, a test controller, test agents, and a comparator in order to test the performance of a plurality of mobile user devices on a wireless network.

The present invention generally relates to the field of cell growth and tissue engineering, in particular, tissue engineered compositions comprising a nanotextured substrate which is structurally configured for growth of cells in an anatomically correct adult phenotype in vitro. In particular, described herein are nanotextured substrates which are structurally configured for the anisotropic organization, maturation, and growth of in vitro-differentiated muscle cells, such as cardiomyocytes, and methods for the production and use thereof in varying sizes, nanotextures and substrate rigidities. In vitro-differentiated cardiomyocytes grown on the nanotextured substrates described herein are better-differentiated and more closely mimic adult cardiac tissue than the same cells grown on a non-textured substrate of the same composition. The nanotextured substrate / cell constructs provide a platform for screening to predict the effect of test agents or drugs on, for example, human cardiac tissue, including patient-derived tissue, or for the identification of agents that effect various cardiac functional parameters.

An auto microfluidic hybridization chip platform is disclosed to provide a hybrid reaction test system with the features of fast reactions, automatic operations, and a convenient platform. The platform includes a flow control system with a platform base, a microfluidic hybridization chip, a microfluidic hybridization chip support, a test agent support of the microfluidic hybridization chip; and a signal detection system. Using a microfluidic pipeline to connect various parts does not only realize automation and a small volume, but also increases the reaction speed.

The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent increases or decreases the expression of the reporter protein thereby identifying a microRNA modulator. Antagonists identified by this screening assay are provided, as are methods for using the same to inhibit microRNA activity and prevent or treat disease.

The present invention provides a novel microscale fluid handling system for initiating, culturing, manipulating and assaying three-dimensional multicellular assembly. The system including a microfluidic device and three-dimensional multicellular tissue surrogate assembly. The device of the invention includes at least one microfluidic channel; and at least one chamber, wherein the walls of the chamber are lined with a cell layer; and wherein fluid medium flows through each of the channels and chambers. Also, disclosed are methods for using the device to introducing test agents to the multicellular assemblies to observe biological responses thereof.

The present invention is directed to a method for determining the effect of each of a plurality of test agents on cells from a subject, and a method to profile patient cell responses to test agents.

Disclosed are embryoid bodies having a uniform size of approximately 415 nm and comprising genetically modified embryonic stem cells, and methods of making same. The genetically uniform embryoid bodies can be multiplexed as one embryoid body per well in a multiwell format, and used as a high to medium throughput screen for test agents that affect the development and homeostasis of animals, including humans. The genetic modification of the embryonic stem cells is a promoter-report-selection construct that enables the selection and detection of cells of a particular lineage in the EB, to determine the effects of a test agent.

A method for identifying test agents that exhibit prebiotic activity on human skin commensal microorganisms and compositions that include such agents. The method includes providing a test culture of a test agent, a human skin commensal microorganism and a minimal carbon medium. The method provides a time efficient and cost effective way to predict in vivo prebiotic activity of a test agent on skin commensal microorganisms.

The present invention is fast detection method of aflatoxin B1 in food and feed. The fast detection method includes the following steps: adding ground sample to be tested in 2-10 g in test tube, adding methanol-sodium chloride aqua of 50-80 % concentration in 10-25 ml, ultrasonic extraction in water bath at 40-60 deg.c, and suction filtering to obtain filtrate in 4-10 ml; adding re-distilled petroleum ether in 2-4 ml into the filtrate, shaking, letting stand to laminate, taking the lower layer of solution in 1-4 ml and adding pure water in 4-20 ml; adding to micro immunoaffinity column of aflatoxin B1, washing with methanol aqua of 10-40 % concentration in 5-10 ml, eluting with methanol in 0.5-2.0 ml, collecting the eluted liquid, adding test agent A in 0.2-1.0 ml; and detecting in fluorescent spectrophotometry or similar instrument. The present invention has the features of simple process, high detection precision and stability, fast detection speed and high safety.

A method of determining toxicity of a test agent in a tissue including A) incubating a test agent within a three-dimensional tissue engineered structure comprising a first mold or polymer scaffold, a semi-permeable membrane, and a second mold or polymer scaffold, wherein the semi-permeable membrane is disposed between the first and second molds or polymer scaffolds, and wherein the first mold or polymer scaffold has microchannels comprising vessels that bifurcate, and B) obtaining information from step A) to assess toxicity.

The invention provides constructs and methods of screening for constructs useful in conferring resistance in plants to pests by gene silencing. The invention also provides pest-resistant plants transformed with the present constructs. One screening method of the invention comprises the steps of: selecting at least one pest target nucleotide sequence, producing a plurality of dsRNA test agents that target the pest target nucleotide sequence, testing and scoring the plurality of dsRNA test agents for toxicity to the pest, and producing a silencing construct based on a superior-scoring test agent.

This invention discloses a test agent box to measure the contents of copper, iron and zinc in blood serum and provides the process method of the agent box. The agent box in this invention dissociates the protein with copper, iron and zinc in blood serum in the buffer liquid system with the surface activity agent, which is compound with the pyridylazo organic compound to make color. The color complex compound has the longest wavelength at 550-600nm.

The invention discloses a colon cancer protein mark parallel test liquid phase chip, which is mainly formed by: micro ball, capture antibody, test antibody and streptomycin-phycoerythrin, wherein the capture antibody with the corresponding micro balls form coupling conjugated, which uses red laser to active the red categorizing fluorescence of the sphere base material and ascertains the type by the different color of the sphere base material; the test antibody is a skin factor mark antibody; the capture antibody and the test antibody can combine with the colon cancer protein mark; the test antibody combines with the streptomycin-phycoerythrin and uses green laser to active the phycoerythrin to measure the report fluorescence molecular number of the sphere base material, which can indirect ascertain the colon cancer protein mark content combines with the sphere base material. The invention also discloses the colon cancer protein mark parallel test liquid phase chip applied in preparing the test agent.

The present invention discloses a manager, a test agent installed on a personal mobile device and methods thereof. The manager comprises: a first network connection module configured to establish a connection with the mobile device through Internet, the mobile device being installed with a test agent for performing test operation on a mobile application on the mobile device; and a security module configured to communicate with the test agent through the first network connection module to make the test agent perform security control on the mobile device. According to the manager, mobile devices, and methods of the present invention, the cost such as maintenance cost of the data center and purchase cost of mobile devices can be reduced dramatically. It is not necessary to analyze market demands since mobile devices owned by the users of the mobile devices are the mobile devices that need to be tested by the tester.

The present invention discloses a device for monitoring chemotaxis or chemoinvasion including a housing comprising: a support member and a top member, the top member mounted to the support member by being placed in substantially fluid-tight conformal contact with the support member. The support member and the top member are configured such that they together define a discrete chamber adapted to allow a monitoring of chemotaxis or chemoinvasion therein. The discrete chamber includes a first well region including at least one first well, the at least one first well configured to received a test agent therein; a second well region including at least one second well, the at least one second well configured to receive a sample comprising cells therein; and a channel region including at least one channel connecting the first well region and the second well region with one another. The second well region is preferably horizontally offset with respect to the first well region in a test orientation of the device.

The invention discloses a film water curing technique of multifunctional hyperfiltration film off-line purifier, which is characterized by the following: the pollution in reverse osmosis membrane system is cleared by carrying out the techniques of film positive washing, negative washing and pure water side pressurization washing; the invention can evaluate and test agent and reverse osmosis membrane property by imitating field producing water condition.